Aandeel 4TZ ORIC PHARMACEUTICALS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen ORIC Pharmaceuticals, Inc. Börse Stuttgart

Aandelen

4TZ

US68622P1093

Beurs gesloten - Börse Stuttgart
Andere beurzen
 08:03:09 02-07-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
7 EUR -1,41% Intraday-grafiek van ORIC Pharmaceuticals, Inc. +6,77% -12,88%
10/06 Transcript : ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM
06/05 ORIC Pharmaceuticals, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!
Gratis inschrijven
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research Annual Meeting
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to S&P Biotechnology Select Industry Index
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Oric Pharmaceuticals Insider Sold Shares Worth $648,380, According to a Recent SEC Filing
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ORIC
  4. Koers 4TZ
  5. Nieuws ORIC Pharmaceuticals, Inc.
  6. Andere talen